Loading...
Loading...
Nabriva Therapeutics AG announced today that the
underwriters of its initial public offering have exercised in full their
over-allotment option to purchase an additional 1,350,000 American
Depositary Shares (ADSs), representing 135,000 of Nabriva's common shares,
at the initial public offering price of $10.25 per ADS, less underwriting
discounts. All of the ADSs in the offering were sold by Nabriva. After the
over-allotment closing, the total number of ADSs sold by Nabriva in its
initial public offering increased to 10,350,000 ADSs, which resulted in
gross proceeds of approximately $106.1 million and net proceeds of
approximately $92.2 million, after deducting underwriting discounts and
estimated offering expenses.
Leerink Partners LLC and RBC Capital Markets, LLC acted as joint
book-running managers for the offering. Needham & Company, LLC and Wedbush
PacGrow acted as co-managers.
A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on September 17, 2015. Copies of
the final prospectus relating to this offering may be obtained from: Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by email at syndicate@leerink.com, or by phone
at (800) 808-7525, ext. 6124, or RBC Capital Markets, LLC, Attention: Equity
Syndicate Department, 200 Vesey Street, 8th Floor, New York, NY 10281, or by
email at equityprospectus@rbccm.com, or by phone at (877) 822-4089.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification of these securities under
the securities laws of any such state or jurisdiction.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in